Page 136 - EJMO-9-2

Eurasian Journal of Medicine and
Oncology
Anticancer effects of phytocomposites

23. Spinello A, Ritacco I, Magistrato A. Recent advances in MD simulations study. RSC Adv. 2022;12(18):11493-11504.
computational design of potent aromatase inhibitors: Open- doi: 10.1039/d2ra00432a
eye on endocrine-resistant breast cancers. Expert Opin Drug
Discov. 2019;14(10):1065-1076. 34. Shen LA, Peng X, Bao Y, et al. Design, synthesis and
biological evaluation of quercetin derivatives as novel
doi: 10.1080/17460441.2019.1646245
β-catenin/B-cell lymphoma 9 protein-protein interaction
24. Ohbayashi N, Murayama K, Kato‐Murayama M, et al. inhibitors. Eur J Med Chem. 2022;247:115075.
Structural basis for the inhibition of cyclin G‐Associated
kinase by gefitinib. ChemistryOpen. 2018;7(9):713-719. doi: 10.1016/j.ejmech.2022.115075
35. Olotu FA, Agoni C, Adeniji E, Abdullahi M, Soliman ME.
doi: 10.1002/open.201800177
Probing gallate-mediated selectivity and high-affinity
25. Masago K, Togashi Y, Fukudo M, et al. Good clinical binding of epigallocatechin gallate: A way-forward in
response to erlotinib in a non-small cell lung cancer patient the design of selective inhibitors for anti-apoptotic Bcl-2
harboring multiple brain metastases and a double active proteins. Appl Biochem Biotechnol. 2018;187(3):1061-1080.
somatic epidermal growth factor gene mutation. Case Rep
Oncol. 2010;3(2):98-105. doi: 10.1007/s12010-018-2863-7
doi: 10.1159/000310830 36. Simanshu DK, Nissley DV, McCormick F. RAS proteins and
their regulators in human disease. Cell. 2017;170(1):17-33.
26. Xia W, Liu Z, Zong R, et al. Truncated ERBB2 expressed
in tumor cell nuclei contributes to acquired therapeutic doi: 10.1016/j.cell.2017.06.009
resistance to ERBB2 kinase inhibitors. Mol Cancer Ther. 37. Hancock JF. Ras proteins: Different signals from different
2011;10(8):1367-1374. locations. Nat Rev Mol Cell Biol. 2003;4(5):373-385.
doi: 10.1158/1535-7163.mct-10-0991 doi: 10.1038/nrm1105
27. Asmane I, Céraline J, Duclos B, et al. New strategies for 38. Ahmadian MR, Stege P, Scheffzek K, Wittinghofer A.
medical management of castration-resistant prostate cancer. Confirmation of the arginine-finger hypothesis for the GAP-
Oncology. 2011;80(1-2):1-11. stimulated GTP-hydrolysis reaction of Ras. Nat Struct Biol.
doi: 10.1159/000323495 1997;4(9):686-689.
28. Roskoski R Jr. STI-571: An anticancer protein-tyrosine kinase doi: 10.1038/nsb0997-686
inhibitor. Biochem Biophys Res Commun. 2003;309(4):709-717. 39. Gimple RC, Wang X. RAS: Striking at the core of the
doi: 10.1016/j.bbrc.2003.08.055 oncogenic circuitry. Front Oncol. 2019;9:965.
29. Lam B, Arikawa Y, Cramlett J, et al. Discovery of TAK-659 an doi: 10.3389/fonc.2019.00965
orally available investigational inhibitor of Spleen Tyrosine 40. Sebti SM. Protein farnesylation: Implications for normal
Kinase (SYK). Bioorg Med Chem Lett. 2016;26(24):5947-5950. physiology, malignant transformation, and cancer therapy.
doi: 10.1016/j.bmcl.2016.10.087 Cancer Cell. 2005;7(4):297-300.
30. Wang M, Yang JCH, Mitchell PL, et al. Sunvozertinib, a doi: 10.1016/j.ccr.2005.04.005
selective EGFR inhibitor for previously treated non-small 41. Sobocińska J, Roszczenko-Jasińska P, Ciesielska A,
cell lung cancer with EGFR exon 20 insertion mutations. Kwiatkowska K. Protein palmitoylation and its role in
Cancer Discov. 2022;12(7):1676-1689. bacterial and viral infections. Front Immunol. 2018;8:2003.
doi: 10.1158/2159-8290.cd-21-1615
doi: 10.3389/fimmu.2017.02003
31. Tron AE, Belmonte MA, Adam A, et al. Discovery of Mcl- 42. Das T, Yount JS, Hang HC. Protein S-palmitoylation in
1-specific inhibitor AZD5991 and preclinical activity immunity. Open Biol. 2021;11(3):200411.
in multiple myeloma and acute myeloid leukemia. Nat
Commun. 2018;9(1):5341. doi: 10.1098/rsob.200411
doi: 10.1038/s41467-018-07551-w 43. Guan X, Fierke CA. Understanding protein palmitoylation:
Biological significance and enzymology. Sci China Chem.
32. Wang L, Yang C, Xie C, et al. Pharmacologic characterization 2011;54(12):1888-1897.
of fluzoparib, a novel poly(ADP‐ribose) polymerase inhibitor
undergoing clinical trials. Cancer Sci. 2019;110(3):1064-1075. doi: 10.1007/s11426-011-4428-2
doi: 10.1111/cas.13947 44. Wang Y, Wang F. Post-Translational modifications of
deubiquitinating enzymes: Expanding the ubiquitin code.
33. Sahu RK, Verma VV, Kumar A, Tandon S, Das BC,
Hedau ST. In silico prediction and interaction of resveratrol Front Pharmacol. 2021;12:685011.
on methyl-CpG binding proteins by molecular docking and doi: 10.3389/fphar.2021.685011

Volume 9 Issue 2 (2025) 128 doi: 10.36922/ejmo.7073